Publication: Effect of 0.3% hydroxypropyl methylcellulose/dextran versus 0.18% sodium hyaluronate in the treatment of ocular surface disease in glaucoma patients: A randomized, double-blind, and controlled study
Issued Date
2015-01-01
Resource Type
ISSN
15577732
10807683
10807683
Other identifier(s)
2-s2.0-84942923561
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Ocular Pharmacology and Therapeutics. Vol.31, No.6 (2015), 323-329
Suggested Citation
Pinnita Prabhasawat, Ngamkae Ruangvaravate, Nattaporn Tesavibul, Maneerat Thewthong Effect of 0.3% hydroxypropyl methylcellulose/dextran versus 0.18% sodium hyaluronate in the treatment of ocular surface disease in glaucoma patients: A randomized, double-blind, and controlled study. Journal of Ocular Pharmacology and Therapeutics. Vol.31, No.6 (2015), 323-329. doi:10.1089/jop.2014.0115 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36754
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Effect of 0.3% hydroxypropyl methylcellulose/dextran versus 0.18% sodium hyaluronate in the treatment of ocular surface disease in glaucoma patients: A randomized, double-blind, and controlled study
Other Contributor(s)
Abstract
© Copyright 2015, Mary Ann Liebert, Inc. Purpose: To compare the efficacy and safety of 0.3% hydroxypropyl methylcellulose/dextran (HPMC/dextran) and 0.18% sodium hyaluronate (SH) in the treatment of ocular surface disease in patients using antiglaucoma drugs containing preservatives. Methods: This was a double-blind, randomized, parallel-group study in 70 glaucoma patients with Ocular Surface Disease Index (OSDI) score greater than 20 points and/or presence of ocular signs. Patients were randomized to receive either preservative-free 0.3% HPMC/dextran (n=35) or preservative-free 0.18% SH (n=35). Treatment was 1 drop in each eye, 4 times a day. Data were collected at baseline, at day 7 and day 28. Results: The groups were homogeneous at baseline. At day 28, both treatments showed significant improvements (P<0.05) in the mean OSDI score, lid skin and lid margin inflammation, conjunctival injection, and expressibility of meibomian glands, corneal staining score, fluorescein tear breakup time (FBUT), and Schirmer I test. However, the mean OSDI score, lid margin inflammation and conjunctival injection showed significant improvements (P<0.05) in the SH group at days 7 and 28, compared to the HPMC/dextran group. FBUT and the Schirmer I test also showed significant improvements (P<0.05) in the SH group compared to the HPMC/dextran group, at day 28. No adverse reactions were observed in either group. Conclusions: Preservative-free artificial tear, 0.3% HPMC/dextran, and 0.18% SH, caused a significant relief of the ocular surface disease in glaucoma patients. However, 0.18% SH led to a greater improvement in ocular signs and symptoms than 0.3% HPMC/dextran.